Peter A Thompson Insider Trading $ADAP Adaptimmune Therapeutics PLC

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for Peter A Thompson.

Your email is safe with us.
The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of Peter A Thompson. Peter A Thompson is Director in RESPONSE BIOMEDICAL CORP ($RPBIF) and Director in ProNAi Therapeutics Inc ($DNAI) and President and CEO in Trubion Pharmaceuticals, Inc ($TRBN) and President, CEO & Treasurer in Trubion Pharmaceuticals, Inc ($TRBN) and Director in Synthorx, Inc. ($THOR) and Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in ALPINE IMMUNE SCIENCES, INC. ($NVLS) and Director in Corvus Pharmaceuticals, Inc. ($CRVS) and Director in Decibel Therapeutics, Inc. ($DBTX) and Director in Silverback Therapeutics, Inc. ($SBTX) and Director in PMV Pharmaceuticals, Inc. ($PMVP) and Director in Prevail Therapeutics Inc. ($PRVL) and Director in Edgewise Therapeutics, Inc. ($EWTX).

Peter A Thompson in Adaptimmune Therapeutics PLC

Trading Symbol: ADAP
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Peter A Thompson: Director
Holdings: 4,902,910 shares
Current Value: $22,210,182
Latest Transaction: Jun 06 2018
$ADAP Market Capitalization: $321.36M
$ADAP Previous Close: $4.53

Last 4 weeks trend: HOLD
Last 3 months trend: HOLD

Latest Insider Trading Transactions of Peter A Thompson in Adaptimmune Therapeutics PLC

	1 Week	2 Weeks	1 Month	3 Months	6 Months	1 Year	2 Years
No. of Purchases	0	0	0	0	0	0	0
Value of Purchases ($)	0	0	0	0	0	0	0
No. of Sales	0	0	0	0	0	0	0
Value of Sales ($)	0	0	0	0	0	0	0

Sentiment: All, ADAP, ALPN, CRVS, DBTX, EWTX, PMVP, PRVL, RPBIF, SRRA, SBTX, THOR, TRBN

Page: 1

Date	Ticker	Company	Owner	Relationship	Transaction	Code	Cost ($)	Shares	Transaction Value ($)	Total Shares	% Holdings
Jun 06 2018	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Sell	S	13.49	1,600	21,584	4,901,310	4.9 M to 4.9 M (-0.03 %)
Jun 06 2018	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Sell	S	13.57	17,100	232,047	4,902,910	4.9 M to 4.9 M (-0.35 %)
Jun 01 2018	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Sell	S	13.49	50,000	674,500	4,920,010	5 M to 4.9 M (-1.01 %)
Jun 01 2018	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Sell	S	13.52	121,000	1,635,920	4,970,010	5.1 M to 5 M (-2.38 %)
May 16 2018	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Sell	S	13.50	10,300	139,050	5,091,010	5.1 M to 5.1 M (-0.20 %)
Mar 29 2018	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Sell	S	11.53	31,983	368,764	5,101,310	5.1 M to 5.1 M (-0.62 %)
Mar 29 2018	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Sell	S	11.50	1,016,084	11,684,966	5,133,293	6.1 M to 5.1 M (-16.52 %)
Jul 03 2017	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Option Exercise	A	0.75	223,779	167,834	223,779
Mar 28 2017	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Buy	P	4.20	1,190,476	4,999,999	6,149,377	5 M to 6.1 M (+24.01 %)
Aug 12 2016	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Option Exercise	A	1.27	186,142	236,400	186,142
May 25 2016	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Buy	P	10.48	518,400	5,432,832	29,753,404	29.2 M to 29.8 M (+1.77 %)
May 25 2016	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Buy	P	10.40	1,191,600	12,392,640	29,235,004	28 M to 29.2 M (+4.25 %)
May 25 2016	ADAP	Adaptimmune Therap ...	Thompson Peter A.	Director	Buy	P	10.04	2,400	24,096	28,043,404	28 M to 28 M (+0.01 %)

Page: 1